2-Amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor

Journal of Viral Hepatitis

Volumn 21, Issue 12, 2014, Pages 843-852

  Cho, M H ^a   Jeong, H ^a   Kim, Y S ^a   Kim, J W ^b   Jung, G ^a  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

antiviral; capsid assembly inhibitor; chronic hepatitis; drug synergism; hepatitis B virus (HBV); structure based drug

Indexed keywords

2 AMINO N (2,6 DICHLOROPYRIDIN 3 YL)ACETAMIDE; ANTIVIRUS AGENT; BCM 598; BCM 599; BCM 600; BCM 601; BCM 602; BCM 603; BCM 604; BCM 605; BCM 606; BCM 607; BCM 608; BCM 609; BCM 610; CORE PROTEIN; LAMIVUDINE; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; CAPSID PROTEIN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG SOLUBILITY; EC50; HEPATITIS B; HEPATITIS B VIRUS; HEPG2 CELL LINE; HYDROPHOBICITY; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN STRUCTURE; VIRUS CAPSID; VIRUS INHIBITION; X RAY CRYSTALLOGRAPHY; BIOLOGY; CELL LINE; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; LIVER CELL; METABOLISM; VIROLOGY; VIRUS ASSEMBLY;

ACETAMIDES; ANTIVIRAL AGENTS; CAPSID; CAPSID PROTEINS; CELL LINE; COMPUTATIONAL BIOLOGY; DRUG SYNERGISM; HEPATOCYTES; HUMANS; LAMIVUDINE; PROTEIN BINDING; VIRUS ASSEMBLY;

EID: 84910623522     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12214     Document Type: Article

References (38)

1. Bader T, Korba B,. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res 2010; 86: 241-245.
2. Kang H, Yu J, Jung G,. Phosphorylation of hepatitis B virus core C-terminally truncated protein (Cp 149) by PKC increases capsid assembly and stability. Biochem J 2008; 416 (1): 47-54.
3. Yokosuka O, Arai M,. Molecular biology of hepatitis B virus: effect of nucleotide substitutions on the clinical features of chronic hepatitis B. Med Mol Morphol 2006; 39 (3): 113-120.
4. Seeger C, Mason WS,. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
5. Hoofnagle JH, Di Bisceglie AM,. Drug therapy: the treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
6. Scaglione SJ, Lok ASF,. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012; 142 (6): 1360-1368.
7. Stray SJ, Zlotnick A,. BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly. J Mol Recognit 2006; 19: 542-548.
8. Wingfield PT, Stahl SJ, Williams RW, Steven AC,. Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly. Biochemistry 1995; 34: 4919-4932.
9. Choi Y, Gyoo Park S, Yoo JH, Jung G,. Calcium ions affect the hepatitis B virus core assembly. Virology 2005; 332: 454-463.
10. Ganem D,. Assembly of hepadnaviral virions and subviral particles. Curr Top Microbiol Immunol 1991; 168: 61-84.
11. Zlotnick A, Johnson JM, Wingfield PW, Stahl SJ, Endres D,. A theoretical model successfully identifies features of hepatitis B virus capsid assembly. Biochemistry 1999; 38 (44): 14644-14652.
12. Ceres P, Zlotnick A,. Weak protein-protein interactions are sufficient to drive assembly of hepatitis B virus capsids. Biochemistry 2002; 41 (39): 11525-11531.
13. Stray S, Bourne C, Punna S, Lewis W, Finn M, Zlotnick A,. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA 2005; 102: 8138-8143.
14. Zlotnick A, Ceres P, Singh S, Johnson JM,. A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J Virol 2002; 76: 4848-4854.
15. Bartenschlager R, Schaller H,. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J 1992; 11: 3413-3420.
16. Wynne SA, Crowther RA, Leslie AG,. The crystal structure of the human hepatitis B virus capsid. Mol Cell 1999; 3 (6): 771-780.
17. Packianathan C, Katen SP, Dann CE III, Zlotnick A,. Conformational changes in the hepatitis B virus core protein are consistent with a role for allostery in virus assembly. J Virol 2010; 84 (3): 1607-1615.
18. Case DA, Darden TA, Cheatham TE, et al,. AMBER 11. San Francisco: University of California, 2010.
19. Momany FA, Rone RJ,. Validation of the general purpose QUANTA 3.2/CHARMm force field. Comp Chem 1992; 13, 888-900.
20. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M,. CHARMM: a program for macromolecular energy minimization and dynamics calculations. J Comp Chem 1983; 4: 187-217.
21. Smith JR, Evans KJ, Wright A, Willows RD, Jamie JF, Griffith R,. Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen. Bioorg Med Chem 2012; 20: 1354-1363.
22. Cho M, Song J, Kim H, Park S, Jung G,. Structure-based design and biochemical evaluation of sulfanilamide derivatives as hepatitis B virus capsid assembly inhibitors. J Enzyme Inhib Med Chem 2013; 28 (5): 916-925.
23. Leis S, Schneider S, Zacharias M,. In silico prediction of binding sites on proteins. Curr Med Chem 2010; 17 (15): 1550-1562.
24. Wu G, Robertson DH, Brooks CL III, Vieth M,. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-Based MD Docking Algorithm. J Comp Chem 2003; 24: 1549.
25. Rao SN, Head MS, Kulkarni A, Lalonde JM,. Validation studies of the site-directed docking program LibDock. J Chem Inf Model 2007; 47 (6): 2159-2171.
26. Venkatachalam CM, Jiang X, Oldfield T, Waldman M,. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 2003; 21: 289-307.
27. Kang HY, Lee S, Park SG, Yu J, Kim Y, Jung G,. Phosphorylation of hepatitis B virus CP at Ser87 facilitates core assembly. Biochem J 2006; 398: 311-317.
28. Shim HY, Quan X, Yi Y, Jung G,. Heat shock protein 90 facilitates formation of the HBV capsid via interacting with the HBV core protein dimers. Virology 2011; 410: 161-169.
29. Malich G, Markovic B, Winder C,. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 1997; 124 (3): 179-192.
30. Chou T,. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58 (3): 621-681.
31. Egan WJ, Lauri G,. Prediction of intestinal permeability. Adv Drug Deliv Rev 2002; 54: 273-289.
32. Cheng A, Merz K Jr,. Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships. J Med Chem 2003; 46: 3572-3580.
33. Nassal M,. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008; 134 (1-2): 235-249.
34. Hu J, Toft DO, Seeger C,. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J 1997; 16: 59-68.
35. Wiersma ST, McMahon B, Pawlotsky JM, et al,. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011; 31 (6): 755-761.
36. Ghany MG, Doo EC,. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49 (S5), S174-S184.
37. Strasser SI,. Drugs in development for the treatment for chronic hepatitis B. Curr Hepat Rep 2012; 11: 111-118.
38. Alexander CG, Jürgens MC, Shepherd DA, Freund SMV, Ashcroft AE, Ferguson N,. Thermodynamic origins of protein folding, allostery, and capsid formation in the human hepatitis B virus core protein. PNAS 2013; 110 (30): E2782-E2791.